Literature DB >> 15899702

Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin.

Nicolas Guyot1, Marie-Louise Zani, Patrick Berger, Sandrine Dallet-Choisy, Thierry Moreau.   

Abstract

A number of serine, cysteine, metallo- and acid proteases were evaluated for their ability to proteolytically cleave the serine protease inhibitor trappin-2, also known as pre-elafin, and to release elafin from its precursor. None of the metalloproteases or acid proteases examined cleaved trappin-2, while serine and cysteine proteases preferentially cleaved trappin-2 within its non-inhibitory N-terminal moiety. Cathepsin L, cathepsin K, plasmin, trypsin and tryptase were able to release elafin by cleaving the Lys 38 -Ala 39 peptide bond in trappin-2. However, purified tryptase appeared to be efficient at releasing elafin. Incubation of trappin-2 with purified mast cells first challenged with anti-immunoglobulin E or calcium ionophore A23187 resulted in the rapid generation of elafin. This proteolytic release of elafin from trappin-2 was inhibited in the presence of a tryptase inhibitor, suggesting that this mast cell enzyme was involved in the process. Finally, ex vivo incubation of trappin-2 with sputum from cystic fibrosis patients indicated the production of a proteolytic immunoreactive fragment with the same mass as that of native elafin. This cleavage did not occur when preincubating the sputum with polyclonal antibodies directed against tryptase. Taken together, these findings indicate that tryptase could likely be involved in the maturation of trappin-2 into elafin under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899702     DOI: 10.1515/BC.2005.047

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  14 in total

1.  Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

3.  Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.

Authors:  Nicolas Guyot; Gudmundur Bergsson; Marcus W Butler; Catherine M Greene; Sinéad Weldon; Efrat Kessler; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Biol Chem       Date:  2010-06       Impact factor: 3.915

Review 4.  New approaches to making the microenvironment of the female reproductive tract hostile to HIV.

Authors:  John V Fahey; Jack E Bodwell; Danica K Hickey; Mimi Ghosh; Maria N Muia; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

5.  A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS.

Authors:  Zhaoxi Wang; Douglas Beach; Li Su; Rihong Zhai; David C Christiani
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-18       Impact factor: 6.914

Review 6.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

7.  Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.

Authors:  Nicolas Guyot; Marcus W Butler; Paul McNally; Sinead Weldon; Catherine M Greene; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

8.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

9.  Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage.

Authors:  Tomasz Kantyka; Ties Latendorf; Oliver Wiedow; Joachim Bartels; Regine Gläser; Grzegorz Dubin; Jens-Michael Schröder; Jan Potempa; Ulf Meyer-Hoffert
Journal:  Biol Chem       Date:  2009-12       Impact factor: 3.915

10.  Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract.

Authors:  Timothy Lahey; Mimi Ghosh; John V Fahey; Zheng Shen; Lucy R Mukura; Yan Song; Susan Cu-Uvin; Kenneth H Mayer; Peter F Wright; John C Kappes; Christina Ochsenbauer; Charles R Wira
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.